Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
traxanox
- Development stage
- Discontinued
- Lead developer
- Mitsubishi Tanabe
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Traxanox (also known as Y-12141) is a pyrimidobenzazepine derivative developed by Yoshitomi Pharmaceutical Industries as an immunomodulatory agent for the treatment of rheumatoid arthritis. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs), traxanox does not inhibit the production of prostaglandin E2 or slow-reacting substances from leukocytes. Instead, its pharmacological profile is characterized by the inhibition of anaphylactoid reactions, suppression of delayed-type hypersensitivity (DTH), and dose-dependent inhibition of adjuvant arthritis in rat models. Its mechanism of action is considered similar to disease-modifying antirheumatic drugs (DMARDs) such as D-penicillamine or levamisole, focusing on the modulation of chronic inflammatory responses rather than acute inflammation.
- Other names
- 9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepine
Beyond the preview
Go deeper on traxanox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on traxanox.